Log In
Print
BCIQ
Print
Print this Print this
 

XEN-D0103

  Manage Alerts
Collapse Summary General Information
Company Xention Ltd.
DescriptionSelective potassium channel Kv1.5 (KCNA5) antagonist
Molecular Target Potassium channel Kv1.5 (KCNA5)
Mechanism of ActionK channel blocker
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationFibrillation
Indication DetailsTreat and prevent atrial fibrillation (AF); Treat paroxysmal atrial fibrillation (AF)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today